EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthetic Preimplantation Factor (sPIF)* Improves Survival and GI Function in Acute Lethal Radiation Syndrome in a Clinically Relevant Murine Model

Roberto Calix, Jean H Wilson, Martin Mueller iD, Peter M Glazer iD, Daniel Zelterman iD, Michelle Deveaux, Caroline Zeiss iD, Arumugam R Jayakumar iD, Eytan R Barnea, Michael J Paidas

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Roberto Calix und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Maternal Fetal Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, FMB 329,…. Hauptthemen laut MEDLINE: Acute Radiation Syndrome, Radiation-Protective Agents, Gastrointestinal Tract. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ionizing radiation (IR) damage, whether intentional, accidental, or therapeutic, reverberates throughout the body. The FDA has approved the use of palliative care and leukocyte growth factors for hematologic depletion (H-ARS), but no treatments have been approved for gastrointestinal damage (GI-ARS). Synthetic PIF (sPIF) safely replicates endogenous PIF’s preventative, reparatory, and regenerative effects. Specifically relevant for radiation-induced damage, sPIF reduces oxidative stress. Subcutaneous (SC) sPIF prevents LD100/30 mortality at 2 w post-treatment and restores GI function post-6Gy exposure (in mice). Daily SC sPIF for 14 d, starting 24 h post-LD85/40 (7.17 Gy) total-body ɣ-irradiation (TBI), increases survival 2.76-fold (14.7% (5/34) to 40.7% (24/59); p = 0.0036) by 4 w post-therapy. All sPIF-treated mice survived for the first 10 d, while only 80% survived in the sham group (p = 0.0034). The sPIF-treated group reached 50% survival at 23 di, while this figure was reached at 19 d in the sham-treated group, with a 21% delay. Importantly, sPIF delays weight loss for up to 25 d, increasing weight by ~12% above baseline and improving colon architecture; in the sham, both weight and colon recovery failed. sPIF partially prevents declines in hemoglobin and platelets, with no bleeding/sepsis observed, while WBC counts declined. sPIF’s safety and lack of deleterious drug-to-drug interaction were documented in a First-in-Human, FDA-approved clinical trial for autoimmune disease. Chronic FDA-guided toxicology/toxicokinetic studies demonstrated NOAEL and the highest safety margin. Collectively, sPIF safely and significantly increases survival, weight gain, and colon crypt scale, directly supporting its suitability for FDA-ARS animal-rule approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Radiation SyndromeRadiation-Protective AgentsGastrointestinal TractAnimalsMiceDisease Models, AnimalMaleFemale

Stichwörter der Autor:innen

*ProprietaryBioIncept, LLCNew YorkSynthetic Preimplantation Factor (sPIF*)hematopoietic and gastrointestinal ARSradiation injurytherapy

Substanzen

Radiation-Protective Agents

Autor:innen und Institutionen

  • Section of Maternal Fetal Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, FMB 329, P.O. Box 208063, New Haven, CT 06520-8063, USA.
  • Maternal and Fetal Medicine, Ochsner Health, 2700 Napoleon Ave. 4th Floor, New Orleans, LA 70115, USA.
  • Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 310 Cedar Street, FMB 220, New Haven, CT 06520-…
  • Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, FMB 337A, New Haven, CT 06520-8063, USA.
  • Institute of Biochemistry and Molecular Medicine, University of Bern, 3010 Bern, Switzerland.
  • Department of Therapeutic Radiology, Yale School of Medicine, P.O. Box 208040, New Haven, CT 06520-8040, USA.

ORCID-Profile: Martin Mueller, Peter M Glazer, Daniel Zelterman, Caroline Zeiss, Arumugam R Jayakumar

Förderung

  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Calix, R., Wilson, J. H., Mueller, M., Glazer, P. M., Zelterman, D., Deveaux, M., Zeiss, C., Jayakumar, A. R., Barnea, E. R., & Paidas, M. J. (2026). Synthetic Preimplantation Factor (sPIF)* Improves Survival and GI Function in Acute Lethal Radiation Syndrome in a Clinically Relevant Murine Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177548

Vancouver

Calix R, Wilson JH, Mueller M, Glazer PM, Zelterman D, Deveaux M, et al. Synthetic Preimplantation Factor (sPIF)* Improves Survival and GI Function in Acute Lethal Radiation Syndrome in a Clinically Relevant Murine Model. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177548

BibTeX
@article{Calix2026,
  author = {Calix, Roberto and Wilson, Jean H and Mueller, Martin and Glazer, Peter M and Zelterman, Daniel and Deveaux, Michelle and Zeiss, Caroline and Jayakumar, Arumugam R and Barnea, Eytan R and Paidas, Michael J},
  title = {Synthetic Preimplantation Factor (sPIF)* Improves Survival and GI Function in Acute Lethal Radiation Syndrome in a Clinically Relevant Murine Model},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177548}
}
Kostenlos starten →